CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Risperidone +2 moredrug
Likely dose
Risperidone 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03887754
NCT03887754Phase 2Completed
CompareCT.gov

Therapeutic Issues for Autism Spectrum Disorders: a Clinical Trial

Minia University·interventional·Posted Mar 25, 2019·Updated Mar 25, 2019

In Brief

A Phase 2 clinical trial evaluating Risperidone, hyperbaric oxygen therapy, and 1 other intervention for Autism Spectrum Disorder. Completed, enrolled 80 participants.

Detailed Summary

This study aimed to show the effects of hyperbaric oxygen therapy and/or Risperidone in improving symptoms of autism

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorder
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 25, 2019
Enrollment StartJan 1, 2016
Primary CompletionJan 1, 2018
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 7.3 years ago

Interventions

Risperidonedrug

It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.

hyperbaric oxygen therapydevice

Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.

Non specific Multivitamindrug

control group received non specific multivitamins as placebo for 8 months.